PRDM2, PR/SET domain 2, 7799

N. diseases: 115; N. variants: 8
Source: ALL
Variant Gene Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs2697963
rs2697963
Entrez Id: 7799
Gene Symbol: PRDM2
PRDM2
CUI: C1314691
Disease:
Age at menarche
0.700 GeneticVariation GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
dbSNP: rs61775135
rs61775135
Entrez Id: 7799
Gene Symbol: PRDM2
PRDM2
CUI: C0007766
Disease:
Intracranial Aneurysm
C 0.700 GeneticVariation GWASCAT Genomic Variations in Susceptibility to Intracranial Aneurysm in the Korean Population. 30823506 2019
dbSNP: rs17350795
rs17350795
Entrez Id: 7799
Gene Symbol: PRDM2
PRDM2
CUI: C0009402
Disease:
Colorectal Carcinoma
0.010 GeneticVariation BEFREE Statistically significant associations were observed between CRC risk and functionally defined candidate SNPs of methylenetetrahydrofolate dehydrogenase 1 (MTHFD1; K134R), 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR; P450R), and PR domain containing 2 with ZNF domain (PRDM2; S450N) and a literature candidate SNP of thymidylate synthase (TYMS; g.676789A>T; nominal P < .05). 26108676 2015
dbSNP: rs1203633
rs1203633
Entrez Id: 7799
Gene Symbol: PRDM2
PRDM2
CUI: C0023467
Disease:
Leukemia, Myelocytic, Acute
0.010 GeneticVariation BEFREE For rs1203633, LCLs with AA genotype were more sensitive to cytarabine-induced cytotoxicity (P = 1.31 × 10(-6)) and AA (vs GA or GG) genotype was associated with poorer OS (P = .015), likely as a result of greater treatment-related mortality (P = .0037) in patients with acute myeloid leukemia (AML). 23538338 2013
dbSNP: rs2744687
rs2744687
Entrez Id: 7799
Gene Symbol: PRDM2
PRDM2
CUI: C0030567
Disease:
Parkinson Disease
0.010 GeneticVariation BEFREE Of 137 informative single-nucleotide polymorphisms, 2 PRDM2 single-nucleotide polymorphisms were significantly associated with an increased risk of Parkinson's disease at the Bonferroni-corrected significance level of 0.0004 (rs2744690: OR, 1.54; SE(logOR), .109; 99.96% CI, 1.05-2.26; uncorrected P = .0001; rs2744687: OR, 1.53; SE(logOR), .113; 99.96% CI, 1.03-2.29, uncorrected P = .0002); the association was significant in the women-only stratum but not in the men-only stratum. 21469201 2011
dbSNP: rs2744690
rs2744690
Entrez Id: 7799
Gene Symbol: PRDM2
PRDM2
CUI: C0030567
Disease:
Parkinson Disease
0.010 GeneticVariation BEFREE Of 137 informative single-nucleotide polymorphisms, 2 PRDM2 single-nucleotide polymorphisms were significantly associated with an increased risk of Parkinson's disease at the Bonferroni-corrected significance level of 0.0004 (rs2744690: OR, 1.54; SE(logOR), .109; 99.96% CI, 1.05-2.26; uncorrected P = .0001; rs2744687: OR, 1.53; SE(logOR), .113; 99.96% CI, 1.03-2.29, uncorrected P = .0002); the association was significant in the women-only stratum but not in the men-only stratum. 21469201 2011
dbSNP: rs1350533716
rs1350533716
Entrez Id: 7799
Gene Symbol: PRDM2
PRDM2
CUI: C0376358
Disease:
Malignant neoplasm of prostate
0.010 GeneticVariation BEFREE This study is the first to provide evidence that the ADPRT V762A-genetic variant contributes to CaP susceptibility and altered ADPRT/PARP-1 enzyme function in response to oxidative damage. 15342424 2004
dbSNP: rs1350533716
rs1350533716
Entrez Id: 7799
Gene Symbol: PRDM2
PRDM2
CUI: C0600139
Disease:
Prostate carcinoma
0.010 GeneticVariation BEFREE This study is the first to provide evidence that the ADPRT V762A-genetic variant contributes to CaP susceptibility and altered ADPRT/PARP-1 enzyme function in response to oxidative damage. 15342424 2004
dbSNP: rs761320613
rs761320613
Entrez Id: 7799
Gene Symbol: PRDM2
PRDM2
CUI: C0600139
Disease:
Prostate carcinoma
0.010 GeneticVariation BEFREE We have conducted two studies to test whether an amino acid substitution variant, ADPRT V762A (T2444C), is associated with prostate cancer (CaP) risk and decreased enzyme function. 15342424 2004
dbSNP: rs761320613
rs761320613
Entrez Id: 7799
Gene Symbol: PRDM2
PRDM2
CUI: C0376358
Disease:
Malignant neoplasm of prostate
0.010 GeneticVariation BEFREE We have conducted two studies to test whether an amino acid substitution variant, ADPRT V762A (T2444C), is associated with prostate cancer (CaP) risk and decreased enzyme function. 15342424 2004